SummaryParticipants in this trial will receive Venetoclax via oral administration, starting with a 20mg dose once daily (QD). Dose escalation will occur weekly in the following progression: 50mg QD, 100mg QD, 200mg QD, 400mg QD, as tolerated.
This trial is treating patients with Chronic Lymphocytic Leukaemia (CLL).
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion